REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

Launched by FERRING PHARMACEUTICALS · Aug 6, 2024

Keywords

ClinConnect Summary

The REKOVELLE PEN study is looking at how well the REKOVELLE medication works for women who are undergoing treatments to help them become pregnant, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). This survey is specifically focused on how this drug helps stimulate the ovaries to produce multiple eggs, which is important for these assisted reproductive technologies (ART). If you are a woman who has used REKOVELLE for this purpose and are willing to participate, you may be eligible for this study.

Since there are no specific exclusion criteria, nearly anyone who has consented and used the medication can take part. Participants can expect to share their experiences and outcomes related to the use of REKOVELLE in their fertility treatments. The information gathered will help improve the understanding of how this medication works in real-life situations, ultimately benefiting future patients seeking help with infertility.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.
• Exclusion Criteria:
• • No exclusion criteria because data are collected under conditions of use in daily practice.